Bio-Techne Corporation reported its financial results for the quarter and six months ended December 31, 2025, revealing a slight decline in revenue compared to the previous fiscal period. The company generated net sales of $295.9 million for the quarter, a decrease of 0.4% from $297.0 million in the same quarter of 2024. For the six-month period, net sales totaled $582.4 million, down 1% from $586.5 million year-over-year. The decline in revenue was attributed to a combination of unfavorable product mix in the Protein Sciences segment and the impact of a business held-for-sale, which offset positive contributions from the Diagnostics and Spatial Biology portfolio.
Despite the revenue decline, Bio-Techne's operating income increased to $54.5 million for the quarter, up from $47.4 million in the prior year, and $102.1 million for the six months, compared to $87.4 million previously. The company reported net earnings of $38.0 million for the quarter, an increase from $34.9 million, and $76.2 million for the six months, up from $68.5 million. The increase in profitability was supported by a reduction in selling, general, and administrative expenses, which fell by 6% to $113.7 million for the quarter, and a decrease in research and development expenses, which declined by 8% to $23.1 million.
Operationally, Bio-Techne's Protein Sciences segment reported net sales of $215.1 million for the quarter, a 2% increase year-over-year, while the Diagnostics and Spatial Biology segment saw a 4% decline to $81.2 million. The company noted that organic revenue for both segments remained flat, with foreign currency exchange providing a favorable impact. The operating margin for the Protein Sciences segment decreased to 39.3%, while the Diagnostics and Spatial Biology segment improved to 10.4%, reflecting the positive effects of the Exosome Diagnostics divestiture.
In terms of strategic developments, Bio-Techne continues to focus on optimizing its manufacturing processes and has engaged in restructuring activities aimed at enhancing operational efficiency. The company has also made significant investments in its product portfolio, including the acquisition of a 19.9% stake in Wilson Wolf Corporation, with plans to acquire the remaining equity interest by December 31, 2027, contingent on meeting certain financial milestones. Looking ahead, Bio-Techne expects to maintain its cash flow and working capital requirements through existing cash reserves and operational cash generation, while also forecasting a tax rate of 26.2% for the remainder of fiscal 2026.
About BIO-TECHNE Corp
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and diagnostic products for research, diagnostics, and bioprocessing markets worldwide. Its two main segments—Protein Sciences and Diagnostics & Spatial Biology—offer biological reagents, protein analysis tools, molecular diagnostics, and spatial biology solutions. Serving academic, pharmaceutical, biotech, and clinical customers, Bio-Techne leverages innovation, quality manufacturing, and a broad global distribution network to support scientific discovery and disease diagnosis.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.